LEESOL
리솔
LEESOL is a Busan-based neuroscience digital health company developing wearable transcranial micro-current brainwave entrainment devices.
About
LEESOL is a Busan-based neuroscience digital health company developing wearable transcranial micro-current brainwave entrainment devices. Its flagship Sleepisol line targets sleep problems, and it uses AI biomarker analysis to extend into stress, depression and cognitive health, with products sold in Japan and the US.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 8
Founders / team· 2
Funding history
- 2026-02-19Series A30亿韩元
Investors · BNK벤처투자, 스페이스타임인베스트먼트, 수인베스트먼트캐피탈, 바인벤처스Source · venturesquare.net ↗
- 2024-10-02Series A40亿韩元
Investors · 바인벤처스, 코오롱제약, 뉴패러다임인베스트먼트, 한국대안투자자산운용, 파인드어스Source · dealsite.co.kr ↗
- 2023-05-18Pre-Series A
Investors · 뉴패러다임인베스트먼트Source · dailymedi.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- LEESOL
LEESOL is a Busan-based neuroscience digital health company developing wearable transcranial micro-current brainwave entrainment devices.
Series A · $1.1B · 2026-02
$1.1B
United States
BusinessLatest roundTotal raisedDate- Precision Neuroscience
building the next generation of brain-computer interfaces (BCIs) with a minimally invasive, high-density implant
Series D+ · $430M · 2026-09
$430M - Coherence Neuro
Closed-loop brain-computer interface system SOMA…
Series A · 2026-10
— - Calm
Subscription app for meditation, sleep and mental health content, plus Calm Health digital mental health offering for employers/health plans/providers
Series C · 2020-12 · Valuation $2.0B
—Valuation $2.0B
China
BusinessLatest roundTotal raisedDate- SiClink
Implantable brain-computer interfaces: in-house flexible neural electrodes and minimally invasive implantation with neural decoding/encoding algorithm…
— - NeuroXess
Implantable flexible brain-computer interface systems (neural signal acquisition chips + decoding algorithms) for patients with neurological disorders
Series B · 2026-10
— - BCI-Sonics
Non-invasive AI ultrasound brain-computer interface (transcranial focused ultrasound neuromodulation + multimodal brain reading and AI neural decoding…
Series A · $42M · 2026-09
$42M
Europe
BusinessLatest roundTotal raisedDate- MyndBlue
Wearable and AI-based remote objective monitoring and early warning for depression and PTSD
— - MintNeuro
Imperial College London spinout developing composable chip modules for neural signal acquisition, electrical stimulation…
Undisclosed · 2026-10
— - Unmind
Enterprise mental health and AI agent platform
Undisclosed · $35M · 2025-08
$35M
Other / unspecified
BusinessLatest roundTotal raisedDate- Hemispheric
AI analysis of non-invasive brain activity data to aid psychiatric diagnosis
2026-07
— - IMeditech
R&D and manufacturing of electrospun nanofiber wound care devices, vascular stents, catheters and neurointerventional devices…
$1.1B
$1.1B - Mentaily
AI diagnostic tools that support mental health professionals with early detection and personalized assessment
Seed · $3M · 2025-05
$3M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
22 Life Sciences deals in the last 24 months · 11 at a nearby stage
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.